Skip to main content

Table 8 Patient demographics and clinical characteristics

From: Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level

 

III

IVA-IVB

Characteristic

TPF(n = 320) No. (%)

PF(n = 167) No. (%)

TP(n = 125) No. (%)

P

TPF(n = 452) No. (%)

PF(n = 173) No. (%)

TP(n = 117) No. (%)

P

Age, y

   

0.106a

   

0.865a

 Median (range)

42(13–70)

44(18–68)

46 (19–64)

 

45(8–74)

45(15–71)

46 (18–71)

 

 < 45

186(58.1)

89(53.3)

59(47.2)

 

225(49.8)

82(47.4)

57(48.7)

 

 ≥ 45

134(41.9)

78(46.7)

66(52.8)

 

227(50.2)

91(52.6)

60(51.3)

 

Gender

   

0.151a

   

0.668a

 Female

78(24.4)

53(31.7)

29(26.1)

 

106 (23.5)

38(22.0)

31(26.5)

 

 Male

242(75.6)

114(68.3)

96(76.8)

 

346(76.5)

135(78.0)

86(73.5)

 

Pathological type

  

0.660b

   

0.370b

 WHO type I

0(0)

0(0)

0(0)

 

3(0.7)

1(0.6)

0(0)

 

 WHO type II

2(0.6)

2(1.2)

0(0)

 

2(0.4)

3(1.7)

0(0)

 

 WHO type III

318(99.4)

165(98.8)

125(100)

 

447(98.9)

169(97.7)

117(100)

 

T stagec

   

0.049b

   

0.426a

 T1

4(1.3)

3(1.8)

1(0.8)

 

7(1.5)

2(1.2)

1(0.9)

 

 T2

41(12.8)

38(22.8)

23(18.4)

 

30(6.6)

11(6.4)

6(5.1)

 

 T3

275(85.9)

126(75.4)

101(80.8)

 

104(48.1)

168(48.4)

118(47.6)

 

 T4

0 (0)

0 (0)

0 (0)

 

311(39.5)

118(34.0)

93(37.5)

 

N stagec

   

< 0.001a

   

0.047 a

 N0

6(1.9)

1(0.6)

5(4.0)

 

9(2.0)

10(5.8)

4(3.4)

 

 N1

95(29.7)

17(10.2)

32(25.6)

 

98(21.7)

40(23.1)

33(28.2)

 

 N2

219(68.4)

149(89.2)

88(70.4)

 

148(432.7)

48(27.7)

43(36.8)

 

 N3

0 (0)

0 (0)

0 (0)

 

197(43.6)

75(43.4)

37(31.6)

 

EBV DNA

   

0.085a

   

0.007 a

 ≥ 1500

188(58.8)

104(62.3)

62(49.6)

 

326(72.1)

127(73.4)

68(58.1)

 

 < 1500

132 (41.3)

63(37.7)

63(50.4)

 

126(27.9)

46(26.6)

49(41.9)

 

RT technique

  

< 0.001a

  

< 0.001 b

 2D RT

5(1.6)

52(31.1)

9(7.2)

 

2(0.4)

49(28.3)

2(1.7)

 

 IMRT

315(98.4)

115(68.9)

116(92.8)

 

450(99.6)

124(71.7)

115(98.3)

 

CCD (mg/m2)

   

0.032 a

   

0.791 a

 Median (range)

160(68–300)

160(40–250)

160(60–300)

 

160(25–300)

160(50–240)

160(20–300)

 

 ≥ 200

85(26.6)

27(16.3)

27(21.6)

 

98(21.7)

36(20.8)

22(18.8)

 

 < 200

235(73.4)

140(83.8)

98(78.4)

 

354(78.3)

137(79.2)

95(81.2)

 
  1. Abbreviations: TPF Taxanes plus cisplatin with fluorouracil, PF Cisplatin with fluorouracil, TP Taxanes with cisplatin, EBV Epstein–Barr virus, CCD Cumulative cisplatin dose during radiotherapy
  2. aP values were calculated by the Chi-square test. bP value calculated with Fisher’s exact test
  3. cAccording to the 7th edition of the UICC/AJCC staging system